2006
Expression of estrogen receptors‐α and ‐β in bladder cancer cell lines and human bladder tumor tissue
Shen S, Smith C, Hsieh J, Yu J, Kim I, Jian W, Sonpavde, Ayala G, Younes M, Lerner S. Expression of estrogen receptors‐α and ‐β in bladder cancer cell lines and human bladder tumor tissue. Cancer 2006, 106: 2610-2616. PMID: 16700038, DOI: 10.1002/cncr.21945.Peer-Reviewed Original ResearchMeSH KeywordsAntineoplastic AgentsBlotting, WesternCarcinoma, Transitional CellCell Line, TumorCell ProliferationEstradiolEstrogen Receptor alphaEstrogen Receptor betaFulvestrantGene Expression ProfilingGene Expression Regulation, NeoplasticHumansImmunohistochemistryMicroarray AnalysisNeoplasm StagingRaloxifene HydrochlorideReverse Transcriptase Polymerase Chain ReactionRNA, MessengerTamoxifenUrinary Bladder NeoplasmsConceptsBladder cancer cell linesExpression of ERbetaCancer cell linesERbeta expressionHuman bladder cancerBladder cancer cellsBladder cancerEstrogen receptorWestern blot analysisT4 tumorsCell linesMetastatic transitional cell carcinomaMuscle-invasive bladder cancerER-alpha mRNA levelsT3/T4 tumorsHuman bladder tumor tissuesRT4 cellsBladder cancer cell growthLevels of ERalphaGrade 3 tumorsCancer cellsInvasive bladder cancerTa/T1Transitional cell carcinomaEffects of estradiol
2002
Raloxifene, a mixed estrogen agonist/antagonist, induces apoptosis in androgen-independent human prostate cancer cell lines.
Kim I, Kim B, Seong D, Lee D, Seo J, Hong Y, Kim H, Morton R, Kim S. Raloxifene, a mixed estrogen agonist/antagonist, induces apoptosis in androgen-independent human prostate cancer cell lines. Cancer Research 2002, 62: 5365-9. PMID: 12235008.Peer-Reviewed Original ResearchConceptsAndrogen-independent human prostate cancer cell linesMixed estrogen agonist/antagonistProstate cancer cell linesHuman prostate cancer cell linesEstrogen agonist/antagonistAgonists/antagonistsCancer cell linesER betaER alphaCell linesDU145 cellsSelective estrogen receptor modulatorsEffects of raloxifeneEstrogen receptor modulatorsPC3M cellsDose-dependent mannerCell deathM raloxifeneWestern blot analysisTime-dependent mannerRaloxifene treatmentReceptor modulatorsBreast cancerPan-caspase inhibitor zVADRaloxifene
1998
The Conventional Transforming Growth Factor-β (TGF-β) Receptor Type I Is Not Required for TGF-β1 Signaling in a Human Prostate Cancer Cell Line, LNCaP
Kim I, Zelner D, Lee C. The Conventional Transforming Growth Factor-β (TGF-β) Receptor Type I Is Not Required for TGF-β1 Signaling in a Human Prostate Cancer Cell Line, LNCaP. Experimental Cell Research 1998, 241: 151-160. PMID: 9633523, DOI: 10.1006/excr.1998.4034.Peer-Reviewed Original ResearchMeSH KeywordsActivin Receptors, Type IDihydrotestosteroneGene ExpressionHumansMaleProstatic NeoplasmsProtein Serine-Threonine KinasesReceptor, Transforming Growth Factor-beta Type IReceptor, Transforming Growth Factor-beta Type IIReceptors, Transforming Growth Factor betaRNA, MessengerSensitivity and SpecificitySignal TransductionTransforming Growth Factor betaTumor Cells, CulturedConceptsHuman prostate cancer cell linesCompetitive quantitative RT-PCRProstate cancer cell linesType II receptorLNCaP cellsII receptorsWestern blot analysisQuantitative RT-PCRCancer cell linesTGF-beta signalingALK-5RT-PCRALK-1Androgen-responsive human prostate cancer cell lineGrowth factor-β receptor type IType II receptor mRNAReceptor type IConcentrations of dihydrotestosteroneTGF-β1 signalingCell linesBlot analysisType INM dihydrotestosteroneReceptor mRNADihydrotestosterone
1996
Transforming growth factor-beta1 is a mediator of androgen-regulated growth arrest in an androgen-responsive prostatic cancer cell line, LNCaP
Kim I, Kim J, Zelner D, Ahn H, Sensibar J, Lee C. Transforming growth factor-beta1 is a mediator of androgen-regulated growth arrest in an androgen-responsive prostatic cancer cell line, LNCaP. Endocrinology 1996, 137: 991-999. PMID: 8603613, DOI: 10.1210/endo.137.3.8603613.Peer-Reviewed Original ResearchConceptsDoses of dihydrotestosteroneProstatic cancer cell linesLNCaP cellsCancer cell linesTGF-beta1 messenger RNART-PCRCompetitive quantitative RT-PCRTGF-beta1 proteinDose-dependent increaseGrowth arrestEnzyme-linked immunoadsorbent assayCell linesTGF-beta1 neutralizing antibodyActivation of latentDose-response curveMessenger RNALNCaP proliferationQuantitative RT-PCRWestern blot analysisNeutralizing antibodiesLinear dose-response curveHigh doseTGF-beta1Immunoadsorbent assayGrowth factorModulation of Sensitivity to Transforming Growth Factor-β1 (TGF-β1) and the Level of Type II TGF-β Receptor in LNCaP Cells by Dihydrotestosterone
Kim I, Zelner D, Sensibar J, Ahn H, Park L, Kim J, Lee C. Modulation of Sensitivity to Transforming Growth Factor-β1 (TGF-β1) and the Level of Type II TGF-β Receptor in LNCaP Cells by Dihydrotestosterone. Experimental Cell Research 1996, 222: 103-110. PMID: 8549651, DOI: 10.1006/excr.1996.0013.Peer-Reviewed Original ResearchMeSH KeywordsBinding, CompetitiveCell CountCell DivisionDihydrotestosteroneDNA, NeoplasmHumansMalePromoter Regions, GeneticProstatic NeoplasmsProtein Serine-Threonine KinasesReceptor, Transforming Growth Factor-beta Type IIReceptors, Transforming Growth Factor betaTranscriptional ActivationTransforming Growth Factor betaTumor Cells, CulturedConceptsTGF-beta receptor type IILNCaP cellsReceptor type IIAndrogen-responsive prostate cancerCharcoal-stripped fetal bovine serumEffect of dihydrotestosteroneGrowth factor-β1Type II TGF-β receptorProstate cancer cellsGrowth inhibitory effectsTGF-β receptorWestern blot analysisDHT concentrationsPresent studyType IIModulation of sensitivityProstate cancerAndrogenic conditionsFactor-β1DihydrotestosteronePotential physiological regulatorsInhibitory effectGene transcriptional activityCancer cellsPhysiological regulatorExpression and localization of transforming growth factor-beta receptors type I and type II in the rat ventral prostate during regression.
Kim I, Ahn H, Zelner D, Park L, Sensibar J, Lee C. Expression and localization of transforming growth factor-beta receptors type I and type II in the rat ventral prostate during regression. Endocrinology 1996, 10: 107-15. PMID: 8838150, DOI: 10.1210/mend.10.1.8838150.Peer-Reviewed Original ResearchConceptsReceptor messenger RNARat ventral prostateType II receptorII receptorsVentral prostateReceptor expressionDay 7Growth factor-beta receptor type IType III receptor expressionTGF betaTGF-beta receptor type IIType IType II receptor proteinType II receptor expressionMessenger RNAEffects of androgensTGF-beta signaling receptorsReceptor type IReceptor type IIStromal-epithelial interactionsType IIProstatic epithelial cellsGrowth factor beta receptorWestern blot analysisImmunohistochemical study
1995
Regulation of proliferation and production of prostate-specific antigen in androgen-sensitive prostatic cancer cells, LNCaP, by dihydrotestosterone
Lee C, Sutkowski D, Sensibar J, Zelner D, Kim I, Amsel I, Shaw N, Prins G, Kozlowski J. Regulation of proliferation and production of prostate-specific antigen in androgen-sensitive prostatic cancer cells, LNCaP, by dihydrotestosterone. Endocrinology 1995, 136: 796-803. PMID: 7530653, DOI: 10.1210/endo.136.2.7530653.Peer-Reviewed Original ResearchConceptsHigher DHT concentrationsEffects of androgensConcentrations of dihydrotestosteroneDHT concentrationsPSA secretionAndrogen receptorCharcoal-stripped fetal bovine serumProstate-specific antigen (PSA) productionHuman prostatic cancer cell linesLow DHT concentrationsProstatic cancer cell linesDose-related mannerNuclear androgen receptorProstate-specific antigenCellular proliferationProstatic cancer cellsProduction of PSADose-dependent inductionWestern blot analysisCancer cell linesProportion of cellsDHT levelsLNCaP cellsM dihydrotestosteronePositive staining